AI in Women's Health: The Regulatory, Data, and Algorithmic Challenges Nobody Talks About

Women's health AI is one of the fastest-growing segments in digital health investment. It's also one of the most technically and regulatorily complex — and most of the complexity is underwritten in the public discourse.

The FemTech sector attracted somewhere around $1–1.5B in disclosed investment in 2024, depending on how the category is defined. Founders are building AI-powered diagnostics for fertility, menstrual health, hormonal conditions, pregnancy, cervical health, and sexual health. Regulators are still catching up. Clinical validation standards are evolving. And the unique data challenges of female physiology — cyclical variation, hormonal complexity, the historical underrepresentation of women in clinical datasets — create algorithmic risks that generic AI guidance doesn't address.

This article is written for the founders and CTOs building in this space. Not for investors evaluating the sector. For the people who have to solve the actual problems.

Companion piece to the rest of our health AI series: SaMD classification for the question of whether your product is a regulated medical device; the engineering reality of clinical-grade AI for what label quality, calibration, and multi-site validation actually require; the six-month roadmap for regulatory program sequencing; and the business case for clinical AI for the strategic frame around the technical work. Many of the principles in those pieces apply directly to women's health AI; this article covers what's specific.

The Data Problem Is More Severe Than in Most Healthcare AI

Every healthcare AI application faces data challenges. Women's health AI faces a specific set of them that compound in ways worth understanding clearly before you design your training pipeline.

Historical underrepresentation in clinical data. Until the 1990s, women were routinely excluded from clinical trials in the US — the rationale being that hormonal variation and potential pregnancy complicated trial results. The NIH Revitalization Act of 1993 mandated inclusion in NIH-funded research. EU guidance on sex and gender considerations in clinical research came significantly later (EMA reflection papers from 2005 onwards), and the legacy in both jurisdictions is a clinical literature where much of the foundational research was conducted on male subjects. AI models trained on this literature, or on datasets derived from it, carry those biases forward.

For a women's health AI company building a diagnostic algorithm, this means your training data may be underrepresenting the population you're building for, even if you're using established clinical datasets. The gap is most pronounced in cardiovascular diagnostics (female presentation of MI differs significantly from male, and historical ECG datasets skew male), psychiatric diagnostics (many diagnostic criteria were developed in male populations), and pain assessment (female pain is systematically undertreated and underrecorded in clinical notes).

Cyclical variation makes "baseline" a moving target. Many physiological parameters in women vary significantly across the menstrual cycle — hormone levels, heart rate variability, temperature, sleep architecture, pain sensitivity, inflammatory markers. An algorithm that doesn't account for cycle phase when interpreting these signals will produce results that are noisy at best and systematically biased at worst.

This is not a trivial engineering problem. Most wearable health platforms don't collect menstrual cycle data as a first-class variable. Most clinical datasets don't include it at all. If you're building a continuous monitoring diagnostic, you need to either collect this data, model it as a latent variable, or explicitly constrain your intended use to contexts where cycle phase is controlled or irrelevant.

Small datasets in underserved conditions. The conditions with the worst clinical outcomes for women — endometriosis, PCOS, pelvic floor disorders, premenstrual dysphoric disorder — are also the conditions with the smallest, most fragmented clinical datasets. Endometriosis affects roughly 10% of women of reproductive age worldwide, causes an average 7–10 year diagnostic delay, and has very limited standardised clinical imaging or biomarker datasets suitable for ML training. Building a diagnostic AI here requires creative data strategy: patient-generated data, wearable sensors, multi-site data sharing agreements, or synthetic data augmentation. Synthetic data is increasingly tolerated by regulators when properly characterised, but it doesn't substitute for real clinical evidence in your validation set.

Label quality and the bias-laundering problem. Supervised learning is bounded by ground truth quality. In women's health this is particularly acute: when training labels come from clinical notes that systematically underweight women's pain reports or attribute symptoms to psychological causes rather than investigating organic pathology, your "ground truth" is laundering historical bias into your model. Multi-rater consensus on training labels and adjudicated test sets where ground truth is clinically confirmed (downstream pathology, outcome data, biomarker confirmation) are essential mitigations for women's health AI specifically — and need to be documented in the regulatory submission.

Sex, gender, and inclusive design. "Women's health" as a regulatory category is starting to require explicit characterisation of who exactly the product is validated for. A device validated on cisgender women may or may not perform appropriately for trans men on testosterone therapy, non-binary individuals, intersex individuals, or post-menopausal populations. The intended-purpose statement should be precise about whether validation is by sex assigned at birth, by hormonal profile, by self-identified gender, or by some combination — and the clinical evaluation should report performance accordingly. Vague "for women" claims are increasingly an audit finding, not a marketing position.

The Regulatory Picture: Four Frameworks Colliding

Women's health AI sits at the intersection of multiple regulatory frameworks, and the interaction between them is not always clearly signposted.

EU MDR / IVDR for diagnostics. Any algorithm that informs a clinical decision about an individual patient — a fertility assessment, an HPV risk prediction, a cervical screening interpretation — is potentially regulated as a medical device under EU MDR or as an in vitro diagnostic under EU IVDR. The IVDR in particular has been a significant source of regulatory uncertainty for digital health companies. Transition periods have been extended multiple times since the original 2022 deadline; for most IVD classes, full IVDR compliance now phases through 2027–2028, with Class D devices facing earlier deadlines. Devices entering the market now need a defined compliance pathway despite the moving deadlines. (For routing software between MDR and IVDR — which catches a lot of women's health founders by surprise — see our SaMD classification piece.)

The work we did with Daye — building an algorithm to predict HPV self-clearance based on vaginal microbiome data — sits squarely at this intersection. The algorithm informs a clinical decision (whether a patient's HPV infection is likely to resolve without intervention) and operates on in vitro diagnostic data (microbiome analysis from a self-sampling kit). Getting the regulatory classification right meant treating the product as IVDR-bound from day one and designing the clinical evidence package against IVDR's performance evaluation requirements rather than MDR's clinical evaluation requirements. The most expensive lesson from that program: the IVDR conformity assessment route has a different evidence structure (analytical performance, clinical performance, scientific validity) than MDR clinical evaluation, and converting between the two mid-program is significantly painful.

EU AI Act for high-risk AI systems. Under the AI Act, women's health AI that is regulated as a Class IIa or higher medical device under MDR/IVDR is automatically classified as high-risk (Annex I route). This is the operative mechanism — not the AI Act's separate Annex III categories around biometric or general health applications, which are used for non-medical-device AI. High-risk classification triggers requirements for conformity assessment, training data governance, transparency to deployers, human oversight, and AI-specific post-market monitoring, applied alongside (not instead of) the MDR/IVDR requirements.

The integration is still being worked through. MDCG, the European AI Office, and notified bodies are aligning on practical conformity assessment integration. The practical implication for founders: design your technical documentation to satisfy both frameworks from the start. Retrofitting AI Act compliance onto an MDR/IVDR-compliant technical file is possible but painful, and August 2026 high-risk provisions are now in force.

NHS DTAC for UK market. Digital Technology Assessment Criteria (DTAC) is the NHS's framework for assessing digital health technologies before they're deployed into NHS services. DTAC covers clinical safety, data protection, technical security, interoperability, and usability. For women's health companies pursuing NHS partnerships — often the fastest path to UK market penetration and clinical data access — DTAC compliance is the de facto entry requirement.

DTAC is not a regulatory approval; it's a procurement filter. NHS trusts use it to shortlist vendors. The clinical safety standard it references (DCB0129) requires a Clinical Safety Officer and a documented clinical safety case. For AI diagnostics, the clinical safety case needs to address how clinician oversight is maintained, what happens when the algorithm produces an uncertain output, and how adverse events are reported and investigated.

FDA pathway for US market. Most women's health AI companies serious about scale need a US strategy alongside Europe. The FDA pathway for SaMD is typically 510(k) (if a substantially equivalent predicate device exists) or De Novo (if not — the path Natural Cycles took for its contraceptive algorithm in 2018). FDA's evidence requirements differ from EU IVDR/MDR, but the underlying clinical data often supports both submissions if planned together from the start. The Predetermined Change Control Plan (PCCP) framework, formalised by FDA in December 2024, is particularly relevant for women's health AI where models often improve significantly with post-launch data accumulation. (The six-month roadmap covers regulatory program sequencing across both jurisdictions.)

Algorithmic Bias in Women's Health: The Questions Regulators Will Ask

Algorithmic bias in healthcare AI is a broad topic. In women's health, there are specific bias patterns that regulators are increasingly asking about and that your technical file needs to address.

Performance disparity across demographic groups. Does your algorithm perform equally well across age groups? Across ethnicities? Across BMI ranges? Across hormonal status (pre-menopausal, peri-menopausal, post-menopausal)? Women's health conditions often have different presentations across demographic groups — endometriosis symptoms, for example, are reported differently across racial groups, partly due to pain undertreatment bias in clinical records. If your training data reflects these biases, your algorithm will too.

EU MDR, IVDR, and the AI Act all require known biases in training data to be identified and mitigated. The mitigation might be data collection (acquiring more representative training data), technical (bias-correcting techniques during training), or operational (constraining the algorithm's intended use to populations where performance has been validated). MDCG 2020-1 on clinical evaluation of medical device software is the relevant guidance for documenting subgroup analysis in the clinical evaluation file.

Ground truth bias in labelled data. This is the deeper bias problem. In women's health, ground truth is often expert clinician annotation — and clinician annotation inherits the biases of clinical practice, including the documented tendency to underweight women's pain reports and to attribute symptoms to psychological causes rather than investigating organic pathology.

If your training labels were produced by clinicians working from clinical notes, and those notes reflect systematic undertreatment of women's symptoms, your ground truth is biased. The algorithm will learn to replicate that bias. Auditing the labelling process and the labellers — including reporting inter-rater reliability and the demographic profile of the labellers — is increasingly an expected component of regulatory submissions, not optional.

Sex and gender data quality. Bias mitigation requires that your dataset actually distinguishes between sex assigned at birth, current hormonal profile, and self-reported gender where these differ. Many clinical datasets collapse these into a single "sex" field that may be unreliable for women's health AI applications. Documenting how your dataset handles this distinction — and how the model handles inputs where the distinction matters — is becoming an explicit notified body question.

Uncertainty communication. Women's health diagnostics often operate in domains of genuine clinical uncertainty — predicting the course of an HPV infection, assessing fertility probability, predicting preterm birth risk. Algorithms that produce confident-sounding outputs in high-uncertainty domains are dangerous. Regulators expect to see how your algorithm communicates uncertainty to clinicians and to patients (where the algorithm has a patient-facing component), what happens when confidence is below a threshold, and how your IFU instructs users to handle uncertain outputs. Confidence calibration analysis on your validation set should be part of the clinical evaluation file.

The Clinical Partnership Problem in Women's Health

Getting clinical data for women's health AI requires clinical partnerships. Getting clinical partnerships requires navigating institutional dynamics that are different from other healthcare AI categories.

GDPR Article 9 and reproductive health data. Reproductive health data is among the most sensitive categories of personal data under GDPR. Data about menstrual cycles, fertility status, pregnancy, sexual activity, or hormonal status triggers Article 9 "special category" provisions, requiring explicit consent (not just opt-in), Data Protection Impact Assessments, careful data minimisation, and specific lawful bases beyond legitimate interest. Cross-border transfers (which are common for cloud-hosted training pipelines) carry additional complexity.

NHS data sharing agreements, in particular, have specific requirements for reproductive health data that can extend the contracting timeline significantly — six to twelve months is realistic, not the three months a founder might budget on a generic data partnership.

HIPAA, post-Dobbs US, and state-level data restrictions. US data protection for women's health AI is more fragmented than founders expect. HIPAA covers health data held by covered entities (providers, insurers, business associates) but does not cover most consumer-facing FemTech apps directly. Post-Dobbs, multiple US states have introduced restrictions on the use, sharing, and out-of-state transfer of reproductive health data (Washington's My Health My Data Act, California's CMIA amendments, others). For US-bound women's health AI, the data governance burden often exceeds the medical device documentation burden — and HIPAA compliance alone is not sufficient.

A women's health AI company operating across the US needs an integrated data governance design that satisfies HIPAA where applicable, applicable state reproductive-health data laws, and any FDA-imposed requirements simultaneously. This is not a Series-B problem; it shapes data architecture from day one.

Adolescent users and parental consent. Menstrual health and fertility AI often has significant adolescent uptake. Under GDPR, children's consent for information society services has a default age of 16 with member-state variation down to 13. Under US law, COPPA (under 13) applies to general consumer apps, with additional state variation. Designing the consent flow, data minimisation, and parental access provisions for adolescent users needs to be explicit in your data governance design — not retrofitted when an audit asks.

IRB / Ethics approval timelines. Women's health research often involves particularly careful ethics review — given the historical exploitation of women in clinical research and the sensitivity of the data involved. Ethics approval (IRB in US, Research Ethics Committee in UK, equivalent national bodies in EU member states) for a clinical dataset collection study in this area should be budgeted at six to twelve months, not three. Designing your study protocol to satisfy ethics requirements from the beginning — rather than amending it after initial review — is worth the upfront investment.

Patient advocacy as a partnership asset. The women's health community has a high degree of patient engagement and advocacy. Conditions like endometriosis and PCOS have active patient communities that can be valuable partners in dataset design and recruitment. Companies that engage these communities early, involve patients in defining the outcomes that matter, and commit to sharing results with the community tend to recruit faster and build more clinically meaningful datasets. Formalising this through Patient Advisory Boards and integrating Patient-Reported Outcome Measures (PROMs) into the clinical evaluation strengthens the regulatory submission as well as the product.

What a Production-Ready Women's Health AI System Actually Looks Like

The difference between a research prototype and a clinical-grade women's health AI system is not primarily algorithmic. The algorithms are usually the least technically challenging part. The difference is in the surrounding infrastructure.

Cycle-aware feature engineering. If your device is intended for use across the menstrual cycle, cycle phase needs to be a first-class feature — either collected directly (via patient-reported data or a validated cycle tracking method) or modelled as a latent variable with appropriate uncertainty propagation. Devices that average across cycle phase silently are either accepting reduced performance or accepting bias depending on the population mix.

Multi-site validation. Single-site validation datasets are increasingly unacceptable to notified bodies for Class IIa and above. Your algorithm needs to demonstrate performance across patient populations from at least two to three independent clinical sites, with different demographics and clinical workflows. Plan for this in your data collection strategy, not as a post-hoc check.

Human oversight and uncertainty communication design. Regulators require that clinical AI systems in high-risk categories maintain meaningful human oversight. For women's health diagnostics, this means designing the user interface and the clinical workflow so that clinicians (or patients, where the device is patient-facing) are interpreting algorithm outputs, not simply acting on them. The algorithm should surface its reasoning — the key features or data points driving its output — in a form the user can evaluate. This is also where the AI Act's human-oversight provisions intersect with MDR/IVDR usability requirements.

Usability evaluation (IEC 62366-1). For women's health AI specifically, usability testing should cover both clinician users (for clinician-facing diagnostics) and patient users (for patient-facing apps), with attention to how uncertainty and risk information is interpreted. Adolescent users, where applicable, require their own usability evaluation. Findings around uncertainty communication and trust are increasingly probed by notified bodies.

Cybersecurity (IEC 81001-5-1). Networked women's health AI carries specific cybersecurity risk because of the sensitivity of the data — reproductive health data is a high-value target and a high-consequence breach. Threat modelling should explicitly consider scenarios specific to reproductive health data exposure (legal consequences post-Dobbs, partner abuse contexts, employment and insurance discrimination). Documentation should follow IEC 81001-5-1 and MDCG 2019-16.

Post-market surveillance and PCCP design. Women's health conditions are dynamic — hormonal status changes, treatments change, the patient population using your device shifts over time, and clinical practice itself evolves (consider how cervical cancer screening guidelines have changed in the past decade). Your post-market surveillance plan needs to describe how you'll detect performance degradation in real-world use, collect feedback from clinicians and patients, and feed that data back into model retraining and clinical evaluation updates.

For ongoing model improvement, the Predetermined Change Control Plan (PCCP) framework lets you pre-authorise specific kinds of model updates — retraining on new data, adjusting thresholds within ranges, expanding to additional conditions — without a full new conformity assessment for each change. Particularly relevant for women's health AI, where post-launch data accumulation often dramatically improves model performance for under-represented subgroups.

Where Vector Labs Fits

We work with healthcare AI founders and med tech companies on regulatory program execution at three points: program scoping (sequencing, timeline reality, build/buy decisions on regulatory infrastructure), technical and clinical documentation (technical file construction, clinical evaluation, AI Act conformity), and notified body interaction (pre-submission, query response, audit preparation). Women's health AI is a particular focus area — we've worked through the IVDR + AI Act + DTAC stack with companies including Daye, and we know where the specific landmines are.

The combination of high investment, genuine unmet clinical need, and underdeveloped competition in this AI niche creates a significant opportunity for companies that solve the real problems rather than the easy ones. The founders who will win in women's health AI are not the ones who build the most technically sophisticated algorithm. They're the ones who navigate the data challenges, design for regulatory compliance from the start, build genuine clinical evidence, and understand that the hardest parts of this work are not algorithmic — they're institutional, ethical, and organisational.

The AI is the relatively easy part. The rest is what separates prototypes from products. If you're scoping a women's health AI program — internally or as part of a build/buy decision — and want to pressure-test the plan against what we've learned, get in touch at vector-labs.ai.